WHEN Oliver Liddle’s knee started to hurt after a game of rugby, he assumed it was from a dodgy tackle. The then-12-year-old ...

Experts at Cancer Research UK revealed these could signal bone cancer, also known as bone sarcoma. This type of cancer is relatively rare in the UK, with an estimated 600 new cases each year.

Lung cancer survival without treatment is shorter than survival with treatment. People with untreated non-small cell lung cancer—the most common type—typically live between five and 12 months after ...

Pembrolizumab is under clinical development by Merck and currently in Phase I for Kaposi Sarcoma. According to GlobalData, Phase I drugs for Kaposi Sarcoma have an 84% phase transition success rate ...

“Stay positive!” Those are the two words a lifelong friend had texted me when I shared that something suspicious had appeared on my breast MRI and required a biopsy. While in theory I agreed there was ...

Joint pain. Bone swelling. These are symptoms that about 1,000 people in the United States begin to feel each year shortly before being diagnosed with osteosarcoma, a type of cancer that starts in ...

A lung biopsy involves the removal of tissue or growths from the lungs. A doctor will use special devices, such as a fine needle, to remove the sample. A lung biopsy can help diagnose lung ...

1 Department of Orthopedic Trauma, Zhuji People’s Hospital of Zhejiang Province, Zhuji, Zhejiang, China 2 Department of Emergency and Critical Care, Shanghai Changzheng Hospital, Shanghai, China ...

Liquid biopsy is one of them. A traditional biopsy usually involves taking a tiny tissue sample from the body to diagnose a disease and to understand the extent of its progression. But liquid ...

OS Ther­a­pies is mov­ing ahead with plans for an ac­cel­er­at­ed ap­proval path­way af­ter its off-the-shelf can­di­date for peo­ple who have had surgery to treat os­teosar­co­ma … ...

The US FDA granted OST-HER2 rare pediatric disease designation for osteosarcoma in 2021. The US FDA rare pediatric disease PRV program aims to incentivize drug development for rare pediatric diseases.